Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia

被引:30
|
作者
Figge, David A. [1 ]
Jaunarajs, Karen L. Eskow [1 ]
Standaert, David G. [1 ]
机构
[1] Univ Alabama Birmingham, Ctr Neurodegenerat & Expt Therapeut, Dept Neurol, Birmingham, AL 35294 USA
来源
JOURNAL OF NEUROSCIENCE | 2016年 / 36卷 / 24期
关键词
DNA methylation; dyskinesia; L-DOPA; DOPA-INDUCED DYSKINESIA; PARKINSONS-DISEASE; GENE-EXPRESSION; PROJECTION NEURONS; NUCLEUS-ACCUMBENS; MEMORY FORMATION; PLASTICITY; 5-HYDROXYMETHYLCYTOSINE; DEMETHYLATION; TRANSCRIPTION;
D O I
10.1523/JNEUROSCI.0683-16.2016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Levodopa-induced dyskinesia (LID) is a persistent behavioral sensitization that develops after repeated levodopa (L-DOPA) exposure in Parkinson disease patients. LID is a consequence of sustained changes in the transcriptional behavior of striatal neurons following dopaminergic stimulation. In neurons, transcriptional regulation through dynamic DNA methylation has been shown pivotal to many long-term behavioral modifications; however, its role in LID has not yet been explored. Using a rodent model, we show LID development leads to the aberrant expression of DNA demethylating enzymes and locus-specific changes to DNA methylation at the promoter regions of genes aberrantly transcribed following L-DOPA treatment. Looking for dynamic DNA methylation in LID genome- wide, we used reduced representation bisulfite sequencingand found an extensive reorganization of the dorsal striatal methylome. LID development led to significant demethylation at many important regulatory areas of aberrantly transcribed genes. We used pharmacologic treatments that alter DNA methylation bidirectionally and found them able to modulate dyskinetic behaviors. Together, these findings demonstrate that L-DOPA induces widespread changes to striatal DNA methylation and that these modifications are required for the development and maintenance of LID.
引用
收藏
页码:6514 / 6524
页数:11
相关论文
共 50 条
  • [21] Levodopa-induced dyskinesia in Parkinson's disease
    Brotchie, JM
    Lee, J
    Venderova, K
    JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (03) : 359 - 391
  • [22] Risk factors for the development of levodopa-induced dyskinesia
    Schaeffer, E.
    Huber, H.
    Liepelt-Scarfone, I.
    Berg, D.
    MOVEMENT DISORDERS, 2012, 27 : S137 - S138
  • [23] LEVODOPA-INDUCED DYSKINESIA - REVIEW, OBSERVATIONS, AND SPECULATIONS
    NUTT, JG
    NEUROLOGY, 1990, 40 (02) : 340 - 345
  • [24] Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
    Zheng, Chang-Qing
    Fan, Hong-Xia
    Li, Xiao-Xian
    Li, Jing-Jie
    Sheng, Shuo
    Zhang, Feng
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [25] Dysregulation of BET proteins in levodopa-induced dyskinesia
    Figge, David A.
    Standaert, David G.
    NEUROBIOLOGY OF DISEASE, 2017, 102 : 125 - 132
  • [26] Measurement of Levodopa-Induced Dyskinesia with Inertial Sensors
    Chung, Kathryn A.
    El-Gohary, Mahmoud
    Lobb, Brenna M.
    McNames, James
    NEUROLOGY, 2009, 72 (11) : A65 - A65
  • [27] Levodopa-induced dyskinesia and striatal signaling pathways
    Pisani, Antonio
    Shen, Jie
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) : 2973 - 2974
  • [28] Clinical Aspects and Management of Levodopa-Induced Dyskinesia
    Tambasco, Nicola
    Simoni, Simone
    Marsili, Erica
    Sacchini, Elisa
    Murasecco, Donatella
    Cardaioli, Gabriela
    Rossi, Aroldo
    Calabresi, Paolo
    PARKINSONS DISEASE, 2012, 2012
  • [29] Molecular mechanisms underlying levodopa-induced dyskinesia
    Calabresi, Paolo
    Di Filippo, Massimiliano
    Ghiglieri, Veronica
    Picconi, Barbara
    MOVEMENT DISORDERS, 2008, 23 : S570 - S579
  • [30] Levodopa-induced dyskinesia in Parkinson’s disease
    J. M. Brotchie
    J. Lee
    K. Venderova
    Journal of Neural Transmission, 2005, 112 : 359 - 391